Hemostasis & Tissue Sealing Agents Market

Market Overview

The global Hemostasis & Tissue Sealing Agents Market was valued at approximately USD 5.3 billion in 2024 and is projected to reach USD 8.7 billion by 2033, growing at a CAGR of 5.7% during the forecast period (2025–2033).

Hemostasis and tissue sealing agents are products that work to control bleeding and facilitate tissue closure during surgical treatment. These agents are used to facilitate coagulation and assist in sealing the tissues, lessening the amount of blood lost and improving surgical outcomes. Topical hemostats, fibrin sealants, and synthetic tissue adhesives are widely used in many surgical specialties, including general, cardiovascular, orthopedic, and trauma surgery. Increasing surgical volumes globally, especially minimally invasive surgical forms of surgery, are helping to spur growth in the market for hemostasis and tissue sealants, as are increased biomaterial technology and sealant formulation technology. The world in general is seeing an aging population, which is leading to an increasing population with chronic diseases and undergoing surgery.

Market Dynamics

Market Drivers

Rising Surgical Volume Due to Trauma, Chronic Diseases, and Elective Procedures

The growing worldwide demand for surgical procedures related to both chronic disease and acute trauma is a leading driver for the global market for hemostasis and tissue sealing agents. According to the Lancet Commission on Global Surgery, over 313 million surgical procedures occur every year around the globe, many of which need blood management and tissue sealing to limit complications from bleeding both intra- and post-operatively.

They are typically used in areas ranging from general surgery to cardiovascular procedures, neurosurgery, and orthopedics, where they help mitigate bleeding and improvements in tissue repair. One major area is the increasing numbers in orthopedic and spinal surgery. The American Academy of Orthopaedic Surgeons (AAOS) estimates that the U.S. performs over 7 million orthopedic surgical procedures each year, and many use topical hemostats and/or sealants.

In addition, emergency trauma surgical cases, especially in road traffic accidents, continue to plague the healthcare system throughout the globe. Those cases are quantified by the World Health Organization (WHO), which estimates that over 1.3 million people die every year from road injuries, and that road traffic injuries are a leading contributor to hospitalizations around the globe, especially in low-and middle-income countries.

This requires effective bleeding control products during trauma surgery, increasing the demand for fast-acting hemostatic agents. The trend toward minimally invasive procedures also increases the need for sealants that can perform effectively in limited surgical fields or in surgical fields that may be technically difficult to reach.

Technological Advancements in Sealant and Hemostat Formulations

The advancement of technology enabling the formulation and delivery of hemostatic agents and tissue sealants is accelerating market growth. Today’s agents are more compatible with the human body, many are absorbable, they work faster, and they are able to work even in patients who are coagulopathic or on anticoagulants. The improvements made through synthetic polymer-based sealants and gelatin- or collagen-based products have widened many applications beyond use in open surgical applications to much less invasive procedures, for example, through laparoscopic and robot-assisted surgery.

Recently, Baxter International, in February 2024, received FDA clearance for their next generation fibrin sealant, Floseal Xtra, which has a faster clotting time and better adhesion in wet surgical fields. BD (Becton, Dickinson and Company) is also using oxidized regenerated cellulose and has developed products optimized for this new robotic surgical markets. Reducing operation time, complications, and improved surgery performance will continue to attract attention from both surgeons and hospital supply chains.

Moreover, as bioengineering efforts have driven the development of the next generation of bioactive sealants that promote hemostasis as well as tissue regeneration, and as clinical trials demonstrate their efficacy and safety, they are being implemented in fast-growing markets such as plastic surgery, gynecology, and transplantation surgery, broadening the total addressable market.

Market Restraint

High Cost of Advanced Hemostatic and Sealant Products and Limited Reimbursement

The principal limitation for widespread acceptance of hemostasis and tissue sealing agents, is significantly greater cost, particularly for enhanced formulations, such as bioengineered fibrin sealants, flowable agents or synthetic polymer-based adhesives. These products will generally have greater costs than conventional surgical materials such as sutures or staples, placing a significant financial burden on the health care facility, especially in low- and middle-income countries.

In most instances, hospitals are required to make purchasing decisions with respect to budget exceeding pricing, forcing them to choose the lower cost alternatives or limit usage to high-risk surgeries. This complication is further worsened by limited or inconsistent reimbursement in many countries. Some developed countries (e.g., U.S. and Western Europe) do have partial reimbursement through Medicare, or private insurers, while many emerging markets do not have structured reimbursement for these products.

For example, patients are often required to pay for topical hemostats and tissue adhesives out-of-pocket in India and certain areas of Southeast Asia, which eliminates use by all but the most affluent, or those in high-end tertiary care environments. This cost-reimbursement mismatch hampers adoption, especially in high-volume procedures or constrained environments where cost efficiency is essential.

In addition, the steep expense of regulatory compliance, clinical trial validation, and storage (in the case of biologics that necessitate storage in refrigeration or a sterile environment) adds to the base cost, creating extra reason for smaller hospitals or outpatient centers to limit inventory of these agents. So, while the clinical advantages are noteworthy, the resource affordability limits generalization across surgical procedures worldwide.

Segmental Analysis

The Hemostasis & Tissue Sealing Agents Market is segmented by product type, by appliction and end-user. Each segment contributes significantly to enhancing surgical outcomes and managing perioperative bleeding.

By Product Type

Topical Hemostats made up the largest share of the market at 41.2% in 2024. They are the most popular hemostatic agent in general surgical applications across specialties.  Gelatin-based and collagen-based topical hemostatic agents are used often in cardiovascular, orthopedic, and general surgeries when rapid bleeding control is required.

These products have gained popularity largely because they are easy to apply, are compatible with other surgical materials, and have a track record of success. Topical hemostatic agents remain in high demand among high-volume surgical centers. Adhesive & Tissue Sealing Agents are predicted to grow at the fastest rate during the eleven-year assessment period. New innovations in fibrin, and synthetic sealants are paving the way for a wider use of adhesive sealing in sealing surgical incisions, fluid leaks, and tissue regeneration.

Their use is increasing in minimally invasive surgeries, especially laparoscopy and robotic surgeries, that require precise sealing.  Mechanical Hemostats including patches and sponges deserve special note as they are being used more frequently- especially in trauma or emergency situations. The increasing rate of accidents put strains on the demand for mechanical hemostats to help control rapid blood loss in the field or critical care setting.

By End-User

Hospitals are the market leader, with a 60.7% market share in 2024 market share driven by the sheer volume of surgical procedures performed in hospitals, including complex cases, emergency procedures, and substantial services that are typically utilized in hospitals. Tertiiary care centers and teaching hospitals often carry the broadest range of hemostatic products, and their access to advanced surgical technologies will support the further use.

The market for Ambulatory Surgical Centers (ASC) is continually growing due to the global transition to outpatient procedures. As hospitals continue to shift towards minimally invasive surgeries, ASCs provide strong options for hemostasis solutions that are effective and quick to minimize procedure time and enhance patient turnover.

Specialty Clinics and Trauma Centers are emerging as new end-users, specifically for mechanical and topical hemostats. They require fast-acting agents for less extensive surgeries and trauma care and their growing location in urban and semi-urban landscapes is driving the expansion of this segment.

By Application

In 2024, General Surgery drove the largest share of the hemostasis & tissue sealing agents market with around 37.8% of the overall market. The high market share can be attributed to the wide use of hemostats and sealants within applications such as hernia repairs, appendectomies, and gastrointestinal surgeries.

Hemostatic agents are used to decrease the time of bleeding, improve complications, and decrease recovery time; therefore, they are widely and establish in the general surgical protocols of many hospitals and outpatients. Cardiac Surgery constitutes a large and growing segment relative to the complex and high-risk procedures performed like coronary artery bypass grafting (CABG), valve replacement, and aortic aneurysm repair.

Rapid and reliable hemostasis is a critical need for many of these procedures, and this has led surgeons to use fibrin sealants, flowable agents, and synthetic adhesives. Neurosurgery is a vital segment. Like cardiac surgery, therapies are performed under conditions where precise hemostatic control and minimal tissue trauma are essential.

Hemostats and sealants are utilized extensively during craniotomies and spinal surgeries where even minor bleeding can lead to disastrous consequences. The emergence of neuro-compatible agents has led to expanding usage within this area Orthopedic Surgery is experiencing increased demand for hemostasis products given the rising number of joint replacements and spinal fixation procedures. Managing bleeding from large bone surfaces and tissues with rich vascularity is essential, and absorbable gelatin sponges and bone waxes are common hemostatic agents.

Hospital bleeding at the Trauma and Emergency Surgery department is also growing as a preferred application. With an increase in road traffic accidents, injuries from industry, and battlefield trauma around the world, the pressing need for immediate effect topical hemostatic agents is increasing. The need for these topical agents is considered in trauma kits, and they are considered when managing patients in prehospital or emergency settings, where hemostatic agents may be utilized to stabilize the patient prior to definitive surgical intervention.

Other Applications, including gynecology, plastic surgery, and urology, help with market growth as the utilization of minimally invasive and cosmetic surgical procedures expands. Among these, tissue adhesives and sealants are preferred in specialties for better cosmetic outcomes and decreased scarring.

Regional Analysis

North America

In 2024, North America accounted for the largest share of the market, roughly 39.4%. This is due to factors that North America has leading surgical infrastructure, high surgical spending, and quick adaption of new hemostatic and tissue-sealing innovations. The United States is the main contributor in this region, due to the number of surgeries performed in these markets (especially trauma care, vascular, and organ transplants).

North America has leading companies, like Baxter, Johnson & Johnson (Ethicon), and BD which have aided in the recovery period due to regulatory approval and reimbursement environments. It also has an increasing number of outpatient surgeries in ambulatory centres in the U.S. and Canada for surgeon to perform quick hemostatic user-friendly products.

Europe

Europe is the second largest regional market (behind North America) with adoption occurring first in Germany, France, the UK and Italy. The growth factors include a growing elderly population, increased surgical volumes, and a willingness to adopt the newest innovation through public health funding for technologies.

The European Commission has noted that there are over 1 million open-heart and general surgeries performed in EU countries annually that often use topical hemostats or other sealants. Furthermore, national healthcare systems in several EU countries, including Austria, the Netherlands, and Scandinavia, encourage evidence-based products for improving outcomes and reducing hospital stays. There has also been an increase in demand for minimally invasive and cosmetic procedures.

Asia-Pacific

Asia-Pacific is estimated to observe the fastest growth, with a projected growth of 7.6% CAGR from 2025-2033. The region is ablaze with demand owing to rapid urbanization, rising income levels and awareness of contemporary surgical practices in countries such as China, India, Japan and South Korea. The region’s growing healthcare infrastructure and increasing burden of chronic conditions, including cardiovascular and orthopedic diseases, are resulting in an increased volume of elective and emergency surgical procedures.

China is also seeing widespread hospital modernization, while India, is seeing greater government initiatives, such as Ayushman Bharat, increasing access to surgical care. In addition, the market is benefiting from local manufacturing of inexpensive hemostats and bioadhesives that serve the immediacy of affordability for the region.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are both experiencing moderate but steady growth in the use of hemostasis and tissue sealing agents. Growth is occurring in countries such as Brazil, Mexico, Saudi Arabia, and South Africa, which all have some urban hospital surgical capacity. More public and private funding are flowing into healthcare, to meet growing public demand for effective trauma and emergency care.

While there are many economic disparities, access in rural areas, and higher costs with more advanced products, international partnerships, training opportunities, and public health campaigns will likely help improve surgical outcomes, and also make these products more visible in these regions.

Recent Development

1. July 2025: Baxter launched Hemopatch, an FDA-approved collagen-based hemostat for open and minimally invasive surgeries.
2. November 2023: Ethicon introduced ETHIZIA™, a synthetic hemostatic patch approved in Europe for rapid bleeding control.
3. January 2024: BD enhanced its Surgicel® oxidized cellulose products for better use in minimally invasive and robotic surgeries.